As Health and Human Services secretary, Robert Kennedy Jr. is a menace to us all and ought to be removed as soon as possible. But he’s right about one matter, and, in a break from his usual practice ...

We have been complaining about direct-to-consumer (DTC) prescription drug advertising for decades. Far too often, the commercials make it seem as if their products are magical. People are seen ...

This article first appeared in the newsletter Your Local Epidemiologist. Pharmaceutical ads in the United States are annoying. Absurd. And almost uniquely American. In fact, only one other high-income ...

Please provide your email address to receive an email when new articles are posted on . The FDA said it will send letters to pharmaceutical companies asking for the removal of “misleading” drug ads.

President Donald Trump is aiming to ramp up scrutiny on pharmaceutical ads — both on TV and social media — as his administration accuses companies of misleading the public about medications and their ...

The U.S. Department of Health and Human Services and the Food and Drug Administration announced major reform on Tuesday that requires pharmaceutical companies to include full safety warnings in direct ...

The Trump administration is targeting "misleading drug advertisements" by initiating rule making to close a 1997 loophole that enables drug advertisers to conceal safety risks in broadcast and digital ...

President Donald Trump has delivered another blow in his ongoing battle with the pharma industry, signing a memorandum on Tuesday that directs the FDA to rein in direct-to-consumer (DTC) drug ...

The Trump administration is planning to ramp up oversight and enforcement of direct-to-consumer prescription drug advertising, but will stop short of an outright ban. President Trump on Tuesday signed ...

FIRST ON FOX: Shortly after announcing a strategy to go after deceptive direct-to-consumer advertising by the pharmaceutical industry, Robert F. Kennedy Jr. and the Department of Health and Human ...

MarketWatch: J.B. Silvers, the John R. Mannix Medical Mutual of Ohio Professor of Health Care Finance, discussed the impact of a new rule requiring drug companies to include the “list prices” in ...